Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Daiichi Sankyo says it has high goals

Daiichi Sankyo says it has high goals

11th June 2009

Daiichi Sankyo has ambitious European targets, it has stated.

Consolidated sales for the 12-month fiscal period ending March 31st 2009 increased more than 23 per cent from the previous year to 490 million euros (417 million pounds).

Although high pre-planned investments in new products made operating profit fall initially, the figure ended being higher than expected.

Now the company wants revenue to grow by over 20 per cent to 592 million euros and operating profits to rise above average.

Executive chairman of Daiichi Sankyo Europe Reinhard Bauer commented on the firm’s goals.

“Our growth targets reflect our confidence that existing products like the mega-seller Olmetec and our new medicines such as Sevikar and the thrombosis inhibitor Efient have won the trust of doctors and patients,” he said.

The company operates in 12 countries across the continent. Germany, France, Spain and Italy are its key markets.

In other news, Daiichi Sankyo promoted the importance for women in Europe to live a healthy lifestyle, while ensuring they get enough nutrients earlier this year.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.